Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (2s-cis)-4-amino-1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)-2(1h)-pyrimidinone
2. 1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)cytosine
3. 2r(-)-cis-hmd-cytosine
4. 2r(-)-trans-hmd-cytosine
5. 2s(-)-cis-hmd-cytosine
6. Bch 4556
7. Bch-4556
8. Beta-l-dioxolane-cytidine
9. Hmd-cytosine
10. Troxacitabine
11. Troxacitabine, 2r(-)-cis-isomer
12. Troxacitabine, 2r(-)-trans-isomer
13. Troxacitabine, 2s(-)-trans-isomer
14. Troxacitabine, Cis-(+-)-isomer
15. Troxacitabine, Trans-(+-)-isomer
1. Troxacitabine
2. 145918-75-8
3. Bch-4556
4. (-)-oddc
5. 4-amino-1-((2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)pyrimidin-2(1h)-one
6. 60kqz0388y
7. Cis-dioxolane-c
8. (-)-1-((2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)cytosine
9. (2s-cis)-4-amino-1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)-2(1h)-pyrimidinone
10. 4-amino-1-[(2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2(1h)-one
11. L-oddc
12. (-)-occc
13. Troxacitabine [usan:inn]
14. Unii-60kqz0388y
15. Nsc668281
16. Lamivudine Impurity I
17. (-)-bch 204
18. Lamivudine Impurity I Rs
19. Troxacitabine [mi]
20. (-)-l-.b.-dioxolanec
21. 4-amino-1-[(2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one
22. Troxacitabine [inn]
23. Troxacitabine (usan/inn)
24. Troxacitabine [usan]
25. Schembl18548
26. ((-))-oddc
27. Troxacitabine [who-dd]
28. Chembl359164
29. Chebi:134886
30. Bcpp000031
31. (-)-l-.beta.-dioxolane-cytosine
32. Zinc1642845
33. Akos015967351
34. Db04961
35. Hy-13770
36. Lamivudine Impurity I [ep Impurity]
37. Cs-0007785
38. Lamivudine Impurity I [usp Impurity]
39. D06255
40. 918t758
41. Lamivudine Related Compound (alpha-troxacitabine)
42. J-525143
43. Q7846702
44. (-)-(2s,4s)-1-[2-hydroxymethyl)-1,3-dioxolan-4-yl]cytosine
45. (-)-l-2',3'-dideoxy-3'-oxacytidine; Troxacitabine; Troxatyl
46. 2(1h)-pyrimidinone, 4-amino-1-((2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-
47. 2(1h)-pyrimidinone, 4-amino-1-(-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-, (2s-cis)-
48. 4-amino-1-[(2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-1,2-dihydropyrimidin-2-one
49. Ltt
| Molecular Weight | 213.19 g/mol |
|---|---|
| Molecular Formula | C8H11N3O4 |
| XLogP3 | -1.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 2 |
| Exact Mass | 213.07495584 g/mol |
| Monoisotopic Mass | 213.07495584 g/mol |
| Topological Polar Surface Area | 97.4 Ų |
| Heavy Atom Count | 15 |
| Formal Charge | 0 |
| Complexity | 328 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in leukemia (myeloid).
Troxacitabine is a beta-L-nucleoside analog, which has shown preclinical antitumor activity in human xenograft tumor models and antileukemic response in patients with relapsed myeloid leukemia.
Anti-HIV Agents
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Troxacitabine is activated by cellular kinases and incorporated into DNA, inhibiting its replication. In contrast to other cytosine nucleoside analogs, troxacitabine is resistant to inactivation by cytidine deaminase (CD).
ABOUT THIS PAGE
A Troxacitabine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Troxacitabine, including repackagers and relabelers. The FDA regulates Troxacitabine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Troxacitabine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Troxacitabine supplier is an individual or a company that provides Troxacitabine active pharmaceutical ingredient (API) or Troxacitabine finished formulations upon request. The Troxacitabine suppliers may include Troxacitabine API manufacturers, exporters, distributors and traders.
Troxacitabine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Troxacitabine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Troxacitabine GMP manufacturer or Troxacitabine GMP API supplier for your needs.
A Troxacitabine CoA (Certificate of Analysis) is a formal document that attests to Troxacitabine's compliance with Troxacitabine specifications and serves as a tool for batch-level quality control.
Troxacitabine CoA mostly includes findings from lab analyses of a specific batch. For each Troxacitabine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Troxacitabine may be tested according to a variety of international standards, such as European Pharmacopoeia (Troxacitabine EP), Troxacitabine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Troxacitabine USP).
LOOKING FOR A SUPPLIER?
